Azithromycin prophylaxis against a chloroquine-resistant strain of Plasmodium falciparum

A. Kuschner, D. G. Heppner, Bt Wellde, T. Hall, I. Schneider, W. R. Ballou, J. C. Sadoff, D. N. Taylor, S. L. Andersen, B. Schuster, G. Foulds

Research output: Contribution to journalArticlepeer-review


Azithromycin has antimalarial activity and favourable pharmacokinetic properties for a prophylactic antimalarial agent. We investigated the ability of azithromycin to prevent malaria in volunteers infected with a chloroquine-resistant strain of Plasmodium falciparum. 4 volunteers received oral azithromycin 500 mg followed by 250 mg daily for 7 further days. Subjects were infected on the third day of azithromycin.3 subjects were protected compared with none of 15 controls. The volunteer not protected by azithromycin had unquantifiable plasma levels of azithromycin, probably because of poor absorption. Azithromycin could be a promising prophylactic agent for P falciparum malaria.

Original languageEnglish (US)
Pages (from-to)1396-1397
Number of pages2
JournalThe Lancet
Issue number8910
StatePublished - Jun 4 1994

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Azithromycin prophylaxis against a chloroquine-resistant strain of Plasmodium falciparum'. Together they form a unique fingerprint.

Cite this